Home › Research › Treatments
Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review
Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E.. Vascular health and risk management, 2010-09-07
Topic: Risk, prevention and care in population studies
Plain-language summary
Background Over the last decade, evidence has accumulated that vascular risk factors increase the risk of Alzheimer disease (AD). So far, few randomized controlled trials have focused on lowering the vascular risk profile to prevent or postpone cognitive decline or dementia. Objective To systematically perform a review of randomized controlled trials (RCTs) evaluating drug treatment effects for cardiovascular risk factors on the incidence of dementia or cognitive decline. Selection criteria RCTs studying the effect of treating hypertension, dyslipidemia, hyperhomocysteinemia, obesity, or diabetes mellitus (DM) on cognitive decline or dementia, with a minimum follow-up of 1 year in elderly populations. Outcome measure Cognitive decline or incident dementia. Main results In the identified studies, dementia was never the primary outcome. Statins (2 studies) and intensified control of type II DM (1 study) appear to have no effect on prevention of cognitive decline. Studies on treatment of obesity are lacking, and the results of lowering homocysteine (6 studies) are inconclusive. There is some evidence of a preventive effect of antihypertensive medication (6 studies), but results are inconsistent. Conclusion The evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters. Several important sources of bias such as differential dropout may importantly affect interpretation of trial results.
What this study adds
Evidence grade: High
This is a pooled review. Overall, evidence that treating vascular risk factors prevents cognitive decline or dementia is scarce and mostly based on secondary outcomes.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ligthart, S. A., Moll van Charante, E. P., Van Gool, W. A., & Richard, E. (2010). Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vascular health and risk management. https://doi.org/10.2147/vhrm.s7343
Vancouver
Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vascular health and risk management. 2010. doi:10.2147/vhrm.s7343. PMID: 20859546.
BibTeX
@article{ligthart2010-20859546,
author = {Ligthart, S. A. and Moll van Charante, E. P. and Van Gool, W. A. and Richard, E.},
title = {{Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review}},
journal = {Vascular health and risk management},
year = {2010},
doi = {10.2147/vhrm.s7343},
pmid = {20859546},
url = {https://doi.org/10.2147/vhrm.s7343}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Main results In the identified studies, dementia was never the primary outcome.
- Studies on treatment of obesity are lacking, and the results of lowering homocysteine (6 studies) are inconclusive.
- There is some evidence of a preventive effect of antihypertensive medication (6 studies), but results are inconsistent.
- Several important sources of bias such as differential dropout may importantly affect interpretation of trial results.
Why it matters
This systematic review found that dementia was never the primary outcome in the identified trials, statins and intensified diabetes control appeared to have no effect on preventing cognitive decline, obesity treatment studies were lacking, homocysteine-lowering results were inconclusive, and antihypertensive evidence was inconsistent. Overall, evidence that treating vascular risk factors prevents cognitive decline or dementia is scarce and mostly based on secondary outcomes.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 57/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Vascular health and risk management) |
| Journal's citation record | 1 / 4 | Vascular Health and Risk Management: journal h-index 99 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question (from PubMed type “Systematic Review”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 4 / 7 | Cited 96 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.3 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 2 / 6 | Cited 1.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Willem A. van Gool: h-index 70 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Amsterdam: institution h-index 1,209 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20859546) |
| Free to read | 2 / 2 | Free to read |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2147/vhrm.s7343
- PubMed: 20859546
- Original source →
- Free full text: Vascular Health and Risk Management →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “diet”
1,116 studies in the library carry the topic tag “diet”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,116 tagged studies.